Seelos Therapeutics to Participate in the 33rd Annual Roth Conference

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually on March 15-17, 2021.

Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls on March 16th and 17th.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony MarcianoHead of Corporate CommunicationsSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Ave., 12th FlNew York, NY 10022(646) 293-2136[email protected] https://seelostherapeutics.com/ https://twitter.com/seelostx https://www.linkedin.com/company/seelos

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-33rd-annual-roth-conference-301229245.html

SOURCE Seelos Therapeutics, Inc.